IEX •
Healthcare •
Biotechnology •
Quote as of 08/19/2026 15:59
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization198.15 mln
Float37.05 mln
Earnings Date11/16/2026
Piotroski F-Score
2
/ 9
Weak
Relative Strength
99
/ 100
Top performer
Debt / Equity
0.55
Moderate leverage
ROE
-123
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Acumen Pharmaceuticals is a drug development company working on new treatments for Alzheimer's disease. Its lead medicine, Sabirnetug, is designed to attack a specific form of amyloid-beta protein in the brain and has already completed one clinical trial, with a second now underway. The company is also working with Halozyme to create a version of Sabirnetug that patients can take by injection under the skin rather than intravenously. Founded in 1996 and based in Newton, Massachusetts, Acumen remains focused on bringing meaningful options to people affected by Alzheimer's.
